Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.55M in total
- 4
- 13F holdersQ2 2026, +26 vs. previous quarter
- 137
- 13F valueReported value at the end of Q2 2026
- $518.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CADL, Q2 2026
No superinvestor reported holding CADL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Candel Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)6:12 PM ET | Sep 10-11 | 1 day | Tak Paul PeterChief Executive Officer | SSale | −280.2K | $11.28 | −$3.16M | −71.2%113.3K after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)4:30 PM ET | Aug 17 | 2 days | Tyagarajan SeshuChief Technology Officer | SSale | −7.00K | $12.00 | −$84.0K | −8.3%76.9K after | 10b5-1 |
| Jul 1, 2026 (view filing)4:22 PM ET | Jun 29 | 2 days | Barone FrancescaChief Scientific Officer | SSale | −23.4K | $10.06 | −$235.8K | −23.3%77.4K after | 10b5-1 |
| Jul 1, 2026 (view filing)4:22 PM ET | Jun 29 | 2 days | Tyagarajan SeshuChief Technology Officer | SSale | −7.00K | $10.02 | −$70.2K | −7.7%83.9K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 23 | 3 daysLate | Manning Paul BDirector | PPurchase | +550.5K | $5.45 | +$3.00M | +24.9%2.76M after | |
| Jul 30, 2025 (view filing) | Jul 28 | 2 days | Nichols William GarrettChief Medical Officer | SSale | −937 | $6.98 | −$6.54K | −1.8%52.5K after | 10b5-1 |
| Jul 2, 2025 (view filing) | Jun 30 | 2 days | Nichols William GarrettChief Medical Officer | SSale | −781 | $5.04 | −$3.94K | −1.5%52.5K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Nichols William GarrettChief Medical Officer | SSale | −45.3K | $8.76 | −$397.0K | −46.3%52.5K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Barone FrancescaChief Scientific Officer | SSale | −32.1K | $8.76 | −$281.6K | −25.0%96.5K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 18-19 | 2 days | Tak Paul PeterChief Executive Officer | SSale | −26.2K | $8.77 | −$229.6K | −10.4%225.7K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Candel Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 10,990,535 | $113.2M | 0.00% | +3,5180.0% | Added |
| RTW Investments, LP | 6,422,018 | $66.1M | 0.56% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,969,040 | $51.2M | 0.00% | +1,859,998+59.8% | Added |
| State Street Corp | 3,549,823 | $36.6M | 0.00% | +2,731,265+333.7% | Added |
| Acorn Capital Advisors, LLC | 3,497,948 | $36.0M | 9.83% | 00.0% | Unchanged |
| Portolan Capital Management, LLC | 3,490,398 | $36.0M | 1.35% | +596,073+20.6% | Added |
| Saturn V Capital Management LLC | 3,303,686 | $34.0M | 4.88% | +407,098+14.1% | Added |
| Vanguard Capital Management LLC | 2,694,040 | $27.7M | 0.00% | +231,283+9.4% | Added |
| Geode Capital Management, LLC | 1,571,021 | $16.2M | 0.00% | +535,586+51.7% | Added |
| Millennium Management LLC | 1,093,905 | $11.3M | 0.01% | +33,819+3.2% | Added |